TY - JOUR T1 - An Integrated 3D bioprinted “disease in a dish” lung cancer model to simultaneously study drug efficacy, toxicity and metabolism JF - bioRxiv DO - 10.1101/2022.05.02.490270 SP - 2022.05.02.490270 AU - NP Nandeesha AU - Madhuri Rotella AU - Subrahmanyam Vangala AU - Uday Saxena Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/05/02/2022.05.02.490270.abstract N2 - Discovery and development of new drugs is a long, expensive and high risk proposition. Millions of dollars spent and decade plus years of time taken to discover a new drug have haunted pharma industry for many years.In part, the reliance on animal models to make go or no go decisions for selecting drugs for human trials has been a problem because animal biology does not capture human disease in entirety. In recognition of this, the last decade has seen the emergence of more human like tools being developed in the hope of better prediction of human outcomes.Towards that end we have developed a 3D bioprinted disease in a dish lung cancer model which uses human cells and includes ability to measure drug efficacy, toxicity and metabolism simultaneously. For drug profiling studies in our disease in a dish model we 3D bioprinted intestinal cells, layered below which were liver cells and finally underneath were target lung cancer cells. The idea was to simulate the path taken by an oral drug which encounters the gut, followed by liver and target organs. We demonstrate here that a 3D bioprinted disease model composed of human derived cells is able to concurrently measure in vitro drug efficacy, toxicity and metabolism. Such humanized models will help make early go or no go decisions on the potential of a drug to enter human trials.Competing Interest StatementThe authors have declared no competing interest. ER -